EUROFINS-TECHNOLOGIES
2.12.2021 09:02:10 CET | Business Wire | Press release
Eurofins Technologies announces the launch of the VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits to provide an efficient solution for SARS-CoV-2 detection in wastewater, including the Omicron variant of concern.
Wastewater-based epidemiology has become an important approach in order to comprehensively monitor the profile of SARS-CoV-2 infections in highly populated areas. Methods to detect SARS-CoV-2 viral RNA in untreated wastewater have advanced over the last number of months. Data has shown that concentrations of viral RNA correlate with trends in reported COVID-19 cases, demonstrating the importance of wastewater testing as a public health tool.
The European Commission has recommended1 the implementation of effective systems for the surveillance of SARS-CoV-2 in wastewater. The VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits delivers an effective solution for SARS-CoV-2 detection in wastewater. The VIRSeek SARS-CoV-2 Wastewater kits detects genes to specifically identify SARS-CoV-2 together with primer/probes sets to evaluate process parameters such as the nucleic acid extraction efficiency, a specific water quality indicator or the impact of matrix inhibition via an internal positive control. The solution is intended to be used by analytical laboratories for SARS-CoV-2 analysis in wastewater samples as part of quality control/quality assurance testing.
These new members of the VIRSeek real-time RT-PCR kit-family for SARS-CoV-2 detection enhance Eurofins Technologies’ VIRSeek SARS-CoV-2 Solution offering by also enabling the detection of mutant variants such as the Omicron variant of concern. The VIRSeek real-time RT-PCR kit-family also incorporates viral concentration workflow and subsequent lysis and isolation of the viral SARS-CoV-2 RNA, using the VIRSeek RNAExtractor AE1 kit for automated platforms.
More information on Eurofins Technologies website.
About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods
Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
1 https://eur-lex.europa.eu/eli/reco/2021/472/oj
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005084/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom